Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.45 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1825727 | 0.80 | CYP1A2 (0.64) | CYP1A2TSHRLMNATYRGRIN2D | |
| SCHEMBL348622 | 0.80 | TSHR (0.52) | CYP1A2TSHRLMNATYRGRIN2D | |
| SCHEMBL1825729 | 0.80 | CYP1A2 (0.64) | CYP1A2TSHRLMNATYRGRIN2D | |
| SCHEMBL868821 | 0.79 | CYP1A2 (0.57) | CYP1A2TSHRLMNATYRGRIN2D | |
| SCHEMBL868822 | 0.79 | CYP1A2 (0.57) | CYP1A2TSHRLMNATYRGRIN2D | |
| SCHEMBL424728 | 0.78 | TSHR (0.73) | CYP1A2TSHRLMNATYRKIF11 | |
| SCHEMBL14205332 | 0.78 | GRIN2D (0.50) | CYP1A2TSHRLMNATYRGRIN2D | |
| SCHEMBL29145894 | 0.78 | CYP1A2 (0.61) | CYP1A2TSHRLMNATYRGRIN2D | |
| SCHEMBL43060 | 0.76 | EPHX2 (0.56) | CYP1A2TSHRLMNATYRGRIN2D | |
| SCHEMBL5057064 | 0.76 | CYP1A2 (0.48) | CYP1A2TSHRLMNATYRGRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017199103-A1 | BENZAMIDE COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-11-23 | — | — | WO | claimed |
| EP-2421852-B9 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-01 | — | — | EP | claimed |
| EP-2421852-B1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | claimed |
| US-8415341-B2 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-04-09 | — | — | US | claimed |
| EP-2431362-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-03-21 | — | — | EP | claimed |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-03-08 | — | — | US | claimed |
| EP-2421852-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20100324015-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | claimed |
| WO-2010124121-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| US-4472412-A | Control of fungi using phenylpropylammonium salts | BASF AKTIENGESELLSCHAFT (DE) | 1984-09-18 | — | — | US | claimed |
| CN-117883308-A | Cosmetic or dermatological composition comprising a merocyanine and an oily phase comprising at least one alkyl or alkylene carbonate | 莱雅公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117285668-A | Ethylene-propylene copolymer catalyst composition and preparation and application thereof | 中国石油天然气股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-105380810-B | Stabilization of cosmetic compositions | 巴斯夫欧洲公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-105985368-B | Metallocene complex containing heteroatom pi-ligand, its preparation method, its catalyst system and application of catalyst system | 中国石油天然气股份有限公司 | 2020-03-10 | — | — | CN | disclosed |
| US-20200062874-A1 | METALLOCENE COMPLEX WITH A HETEROATOM-CONTAINING PI-LIGAND AND PREPARATION METHOD THEREFOR, CATALYST SYSTEM CONTAINING THE SAME AND USE THEREOF | PETROCHINA COMPANY LIMITED (CN) | 2020-02-27 | — | — | US | disclosed |
| US-4310679-A | Equilibrating organosiloxanes with fluorine- and sulphonyl-containing catalysts | BAYER AKTIENGESELLSCHAFT (DE) | 1982-01-12 | — | — | US | disclosed |
| US-4278554-A | METHYLENE-BRIDGED O-ALKYLPHENOLIC COMPOUNDS DIALKYLPHENOL TERMINATED | ETHYL CORPORATION (US) | 1981-07-14 | — | — | US | disclosed |
| US-4222884-A | PHENOLIC COMPOUND | ETHYL CORPORATION (US) | 1980-09-16 | — | — | US | disclosed |
| US-4107138-A | Phosphonous and thiophosphonous acid ethers as stabilizers for organic materials | SANDOZ LTD. (CH) | 1978-08-15 | — | — | US | disclosed |
| US-3987097-A | INCREASING AFFINITY FOR ANIONIC DYES | SANDOZ LTD. (CH) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324015-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPC | CYP1A2 178/4885TSHR 1108/4885LMNA 1955/4885 |
| US-20200062874-A1 | METALLOCENE COMPLEX WITH A HETEROATOM-CONTAINING PI-LIGAND AND PREPARATION METHOD THEREFOR, CATALYST SYSTEM CONTAINING THE SAME AND USE THEREOF | ORC3, ORMDL3, OR51E2 | CYP1A2 1052/4885TSHR 1986/4885LMNA 3560/4885 |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACSL3, SLCO4C1, SLC38A7 | CYP1A2 148/4885TSHR 2633/4885LMNA 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.